Biodegradable Polymersomes for the Delivery of Gemcitabine to Panc-1 Cells.

Published

Journal Article

Traditional anticancer chemotherapy often displays toxic side effects, poor bioavailability, and a low therapeutic index. Targeting and controlled release of a chemotherapeutic agent can increase drug bioavailability, mitigate undesirable side effects, and increase the therapeutic index. Here we report a polymersome-based system to deliver gemcitabine to Panc-1 cells in vitro. The polymersomes were self-assembled from a biocompatible and completely biodegradable polymer, poly(ethylene oxide)-poly(caprolactone), PEO-PCL. We showed that we can encapsulate gemcitabine within stable 200 nm vesicles with a 10% loading efficiency. These vesicles displayed a controlled release of gemcitabine with 60% release after 2 days at physiological pH. Upon treatment of Panc-1 cells in vitro, vesicles were internalized as verified with fluorescently labeled polymersomes. Clonogenic assays to determine cell survival were performed by treating Panc-1 cells with varying concentrations of unencapsulated gemcitabine (FreeGem) and polymersome-encapsulated gemcitabine (PolyGem) for 48 hours. 1 μM PolyGem was equivalent in tumor cell toxicity to 1 μM FreeGem, with a one log cell kill observed. These studies suggest that further investigation on polymersome-based drug formulations is warranted for chemotherapy of pancreatic cancer.

Full Text

Duke Authors

Cited Authors

  • Sood, N; Jenkins, WT; Yang, X-Y; Shah, NN; Katz, JS; Koch, CJ; Frail, PR; Therien, MJ; Hammer, DA; Evans, SM

Published Date

  • January 2013

Published In

Volume / Issue

  • 2013 /

PubMed ID

  • 26167335

Pubmed Central ID

  • 26167335

Electronic International Standard Serial Number (EISSN)

  • 2090-7818

International Standard Serial Number (ISSN)

  • 2090-9918

Digital Object Identifier (DOI)

  • 10.1155/2013/932797

Language

  • eng